Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19
Nephrology Dialysis Transplantation
; 36(SUPPL 1):i540, 2021.
Article
in English
| EMBASE | ID: covidwho-1402528
ABSTRACT
BACKGROUND AND AIMS:
Immunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during COVID-19 must be characterized.METHOD:
Herein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units who survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and immunologic events was evaluated.RESULTS:
At least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent. Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19. Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes neither de novo donor specific antibodies were observed up to 3 months after discharge, and no significant changes occurred in calculated panel reactive antibodies. Acute graft dysfunction was common (55%) and the severity was related to tacrolimus trough levels, which were higher in patients receiving antivirals. At the end of follow-up, all patients recovered baseline kidney function.CONCLUSION:
Our observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely minimized.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Nephrology Dialysis Transplantation
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS